The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...
Pancreatic ductal adenocarcinoma remains a challenge to treat due to its complex biology and resistance mechanisms.
Alfa, MD, discusses the findings and key takeaways from the SUMMIT trial, which evaluated the use of neratinib for the ...
Potential practice-changing therapies in gynecologic cancer include the emergence of carboplatin, paclitaxel, and PD-1 ...
During a Case-Based Roundtable® event, Daniel J. George, MD, discusses how often community oncology participants see patients ...
A new drug application seeking the accelerated approval of dordaviprone forrecurrent for H3K27M-mutant diffuse glioma ...
Experts examine both overall survival outcomes and independent review committee–assessed progression-free survival data from ...
Sacituzumab govitecan, currently indicated in triple-negative breast cancer (TNBC), is undergoing evaluation in NSCLC. In ...
On December 20, 2024, the FDA granted accelerated approval to the combination of encorafenib (Braftovi), cetuximab (Erbitux), ...
A panelist discusses how molecular testing for patients with MBC who relapse during or shortly after adjuvant endocrine ...
During an in-person Community Case Forum event in Miami, Florida, Mike Cusnir, MD, discussed the ARANOTE study outcomes ...
Panelists discuss how to approach treatment decisions for a 74-year-old patient with transplant-ineligible newly diagnosed multiple myeloma patient, considering factors such as age, comorbidities, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback